Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

th, 2009 at 4:00 p.m. at the Gallery of the TSX Broadcast & Conference Centre, The Exchange Tower, 130 King Street West, Toronto, Ontario.

The management proxy circular documents and annual financial documents have been mailed to shareholders and are available online at www.ymbiosciences.com, www.edgar.com and www.sedar.com.

Cancellation of AIM Listing

YM also announced that trading of the Company's Common Shares on the AIM market of the London Stock Exchange ("AIM") was cancelled on October 26, 2009. YM shares had traded on AIM since 2002, however the majority of YM's shareholder base and liquidity now result from its Canadian and US listings. Therefore YM concluded that the additional costs associated with maintaining a listing on AIM were not justifiable given its North American focused shareholder base. The cancellation of trading of its common shares on AIM was effective at 7:00 a.m. (GMT) on Monday, October 26, 2009 (the "Cancellation Date").

Following the cancellation of the Company's Common Shares on AIM, shareholders may continue to hold their shares and may continue to trade such shares on either the TSX under the symbol 'YM' or the NYSE Amex under the symbol 'YMI'. YM does not expect the liquidity or marketability of its common shares to be materially affected by the AIM delisting.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversifie
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
(Date:7/27/2015)... ... July 27, 2015 , ... Production of high tenacity ... past few years in the EU. For instance, it surpassed the EUR 106 million ... million mark in 2010. Germany is a major producer, while Italy is a key ...
(Date:7/27/2015)... , July 27, 2015 According ... by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative ... , Europe , Asia-Pacific ... 2019", The global biopreservation media market was valued at $247.7 ... $571.5 million by 2019, at a CAGR of 18.2% between ...
(Date:7/26/2015)... ... July 26, 2015 , ... Maine Standards Company, LLC ... linearity test kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 ... the CLSI recommended “equal delta” method for linearity testing and is liquid, ready-to-use. ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2
... SAN DIEGO, March 30 BrainCells Inc. (BCI), ... using its proprietary platform technology to identify novel ... today the appointment of Dr. Philip Jochelson as ... business officer. Both have extensive experience in the ...
... informed consent software for clinical research trials has named Jovianna ... over 20 years experience driving new pharmaceutical therapeutics and devices ... clinical development to commercialization. , ... ...
... ITMN ) today announced that Daniel G. Welch, ... at Citi,s 4th Annual Biotech Day in New York City ... access a live audio webcast of the presentation, investors and ... page of InterMune,s corporate website at www.intermune.com . ...
Cached Biology Technology:BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer 2BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer 3Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer 2
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. ... molecular diagnostics, today announced the launch of a ... Company,s Precision Cancer Monitoring℠ (PCM) technology for predicting ... one or a combination of the novel immunotherapy ... (nivolumab), a PD-1 inhibitor. The 50-patient study will ...
(Date:7/2/2015)... , June 25, 2015 ... the addition of the "Natural Language Processing ... (Recognition, IVR, OCR, Pattern & Image Recognition) - ... offering. The key vendors occupying the ... IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute ...
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... Molecular and Cell Biology (IMCB) and the Singapore Bioimaging ... controls both obesity and atherosclerosis. The team demonstrated, for ... gene were resistant to weight gain and atherosclerosis via ... its downstream signalling molecule mTor. These groundbreaking findings were ...
... Function and significance of the biological clocks in polar ... Institute entitled PolarTime starting July 1st, 2012. It is ... Helmholtz Association. PolarTime, coordinated by the Alfred Wegener Institute ... up to five years with approximately three million euros ...
... in German . , One bit of ... about 3 million magnetic atoms. Researchers from Karlsruhe, Strasbourg, and ... per molecule. By an electric pulse, the metal-organic molecule can ... low-conductive, non-magnetic state. This novel correlation for molecules is now ...
Cached Biology News:Groundbreaking discovery of mechanism that controls obesity, atherosclerosis 2Just a question of time? 2Just a question of time? 3Nature: Molecule changes magnetism and conductance 2
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: